A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Steatohepatitis
Hepatic Impairment
Cirrhosis

Interventions

DRUG: TVB-2640 - 50 mg

Sponsor

Sagimet Biosciences Inc.